High-fidelity continuous monitoring of physiology anywhere with RDS

Talks

Towards personalised neuromodulation in mental health: A non-invasive avenue of network research into dynamic brain circuits and their dysfunction
Prof. Alexander Sack
Done
The condition and perturb approach, a new protocol for preoperative language mapping in patients with brain tumors: First results of intraoperative validation
Tammam Abboud, MD
Done
Clinical brain-computer interfaces: Challenges and new applications
Prof. Surjo Soekadar, MD
Done
The potential of brain rhythms to gauge the vulnerability of an individual to developing chronic pain
Prof. Ali Mazaheri
Done
From one-size-fits-all psychiatry to stratified psychiatry: Brain markers and heart-brain-coupling
Martijn Arns, PhD
Done
The Berger’s discovery revisited: How and why the brain’s dominant rhythm relates to cognition
Tzvetan Popov, PhD
Done
Mapping and targeting with TMS
Prof. Thomas Knösche
Done
Two clinical applications of hdEEG: Kinesthetic illusion and consciousness in sleep
Jan Hubený, Ing.
Done
Real brains in virtual worlds
Prof. Klaus Gramann
Done
Own data, not hardware
Cecilia Mazzetti, PhD
Done

11/5/22, 10:15 AM - 11/5/22, 10:45 AM (Europe/Amsterdam) (30 minutes)

Louis Mayaud, PhD

Chief Technology Officer at RDS (Rhythm Diagnostic Systems)

Louis Mayaud is currently leading technology and innovation at Rhythm Diagnostic Systems (RDS) the leading vital sign monitoring company. He earned a D.Phil. in Healthcare Innovation from the Institute of Biomedical Engineering (IBME) at University of Oxford. This work was completed with the MIMIC-3 relational database at Harvard-MIT and using evolutionary methods such as Genetic Algorithm for concomitant feature selection and non-convex parameter optimisation. During his time, Louis was principal investigator of a project aiming at the transfer of communication Brain-Computer Interface to the bedside of Locked In Syndrome ICU patients. During the 5 years that followed, Louis orchestrated in-silico and clinical innovation at Mensia Technologies, the emerging leader of home-based neuropsychiatric medical devices. Specifically, he instigated and supervised the three-year-long NEWROFFED European Project (H2020 SME biomarker - €3.6m). This international initiative led to the most ambitious multicentric randomised controlled trial in the field to date and the CE clearance of the first medical device (class IIa) for the home-based treatment of attention disorders (ADHD)

Monitoring the Autonomous Nervous System in the ecological environment for an extended period of time remains a challenge that impairs longitudinal neuroscience research in-situ for a large cohort of subjects. To ensure subject compliance and value to research, there is a need for high-fidelity monitoring sensors that are seamless for the patients, can last for at least a week of continuous monitoring and collect raw high-quality data. To maintain control of the session, the data need to be transfered effectively from the patient to an online data platform in a user transparent connectivity solution. Having the data available in real time in the cloud, data quality and subject compliance could be monitored in real time and physiological parameters of interest could be derived and trigger subsequent notifications. The online data could be queried and large retrospective datasets for your research can be inspected. RDS is a startup from France that is tackling these issues with MultiSense, an innovative medical device that removes some of these barriers and collects multimodal data (ECG, PPG, Accelerometer, skin temperature, and piezo) and derived features (HR, RR, Spo2, activity, posture) and streams them into a regulatory compliant e-Health platform. I will present the innovation behind the system and how it enables novel types of longitudinal studies as well as diagnostics.